aiGENE, Inc

First low cost, in office, test to determine if a cancer regimen is working. A novel, method measures cancer DNA in the blood. 3:1 $ leverage/matching grant.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Aurora, CO, USA
  • Currency USD
  • Founded September 2020
  • Employees 2
  • Incorporation Type C-corp
  • Website aiGENE.us

Company Summary

Cancer therapies may cost $10,000 or even $25,000 a month, they cause side effects and most importantly, they fail to work, or stop working, more often than they succeed. aiGENE will offer the first low cost, in office measurement to determine at the time of the first visit after treatment starts, rather than after months, if a therapy is working or if it should be changed to one more appropriate for that person.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free